Macrogen Inc (038290) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Macrogen Inc KRW 4,457, price KRW 12,090, upside -63.1%, quality 48 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Macrogen Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 10,700 KRW – 36,122 KRW · fair‑value band 3,342 KRW – 5,267 KRW · the 12,090 KRW price screens above the 4,457 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 24, 2026.
Follow Macrogen in your weekly email
Every Wednesday you see whether Macrogen is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Macrogen, Inc. provides genetic and genomic analysis research services in South Korea and internationally.
Show more
Macrogen, Inc. provides genetic and genomic analysis research services in South Korea and internationally. It offers next generation sequencing (NGS) services, such as whole genome, exome, targeted, transcriptome, metagenome, epigenome, and single cell multi-omics sequencing, as well as whole genome resequencing; and standard, difficult template, and 16S/18S/26S rRNA and ITS region sequencing services, as well as animal/plant identification, PCR optimization/amplification, pyrosequencing, NGS validation, multi locus sequence typing analysis, sanger sequencing, primer walking, and cloning services. The company also provides fragment analysis services; clinical diagnostic; personal genome analysis; genetic testing services for research purposes, such as messenger RNA, microRNA, single nucleotide polymorphism, comparative genome hybridization, and DNA methylation; oligo and gene synthesis; and clustered regularly interspaced short palindromic repeats design and synthesis material, gRNA synthesis, validated gRNA, and gRNA plasmid services. In addition, it offers genetically engineered mice for use in biological and medical research to identify the functions of human genes; transgenic mouse in which a specific gene has been inserted to study the function of the gene; and GEM-related services, including mass reproduction, microinjection, mouse line recovery, embryo freezing and reproduction, and KO/TG mouse maintenance. Further, the company provides covid-19 test kit under the Axen name, as well as operates smart mobile lab for covid-19 testing. Additionally, it offers iD4U genetic testing services for kinship and personal identification; and myPETGENE genetic testing service for pets. Macrogen, Inc. was founded in 1997 and is headquartered in Seoul, South Korea.
Stock analysis
Macrogen Inc (038290) currently trades at 12,090 KRW, while our model-based Fair Value estimate is 4,457 KRW, implying the stock looks roughly 171.3% overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of 10,514 KRW per share, and 1 of the 14 models we run sit above the 12,090 KRW price.
Bear case: the Earnings-Based group reads lowest at 2,180 KRW, and 13 of the 14 models stay below the price. Evidence for this calculation is low.
Scenario range: 3,342 KRW (bear) to 5,267 KRW (bull), the price of 12,090 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Macrogen Inc reported revenue of 195B KRW in FY2025 versus 129B KRW in FY2021, a compound +10.9%/yr. Reported net income was 2.0B KRW in FY2025, compounding +16.2%/yr from FY2021.
Key figures
Market cap 131B KRW (≈ $91.8M) · P/S ratio 0.88 · Dividend yield 1.9% · Net margin 1.0% · Return on equity −502% · Return on assets (EBIT) −1.7% · Operating margin 3.3% · Revenue (TTM) 138B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).
What moves the price
The share trades about 38% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −32% fair-value upside, at −63%, 038290 screens richer than that median.
Fair Value models
Bear 3,342 KRWFair Value 4,457 KRWBull 5,267 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.47/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+43.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.6%
Start year 2020 (pandemic). Over 10 years: +9.4% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.7%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−45.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year−47.2%
Dividend (yield on the price)1.9%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−47% vs −9%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.10% → 0%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Biotechnology & Medical Research” was too small, so the broader sector is used.)Health Care · 2614 stocks
Beats the sector median on 2/8 measures
Overall it trails its sector peers.
Valuation
Quality Score48 · Below median
Fair Value upside−63% · Bottom 25%
Profitability
Return on assets1% · Below median
Net margin (TTM)2% · Below median
Operating margin (TTM)3% · Below median
Growth and dividend
Revenue growth25% · Top 25%
Dividend yield (TTM)1.9% · Above median
Balance sheet
Debt / equity0.10× · Above median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 6
FUTURE (revenue growth)100· sector 21
PAST (return on equity)0· sector 13
HEALTH (low debt)95· sector 96
DIVIDEND (yield)38· sector 33
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Macrogen Inc Fair Value". https://www.fairvalue-calculator.com/stock/038290
Frequently asked questions
Is Macrogen Inc (038290) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 4,457 KRW versus a price of 12,090 KRW, about −63% upside (overvalued).
What is the fair value of 038290?
Our model-based fair value for Macrogen Inc is 4,457 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 12,090 KRW.
What is the quality score of 038290?
Macrogen Inc has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Macrogen Inc (038290)?
Our model-based price target is the fair value of 4,457 KRW (as of Sep 24, 2026) from 14 valuation models. Cautious scenario 3,342 KRW, optimistic scenario 5,267 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Macrogen Inc stock forecast for 2026?
Our models put fair value at 4,457 KRW, about −63% upside versus a price of 12,090 KRW (overvalued). Cautious scenario 3,342 KRW, optimistic scenario 5,267 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Macrogen Inc (038290)?
Macrogen Inc reported trailing-twelve-month revenue of about 138B KRW (latest available figure, as of Sep 24, 2026).
Does Macrogen Inc pay a dividend?
Macrogen Inc currently shows a dividend yield of about 1.90% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Macrogen Inc (038290)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Macrogen Inc it is 4,457 KRW per share (as of Sep 24, 2026), against a price of 12,090 KRW. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is Macrogen Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 038290 trades above its calculated fair value: price 12,090 KRW, fair value 4,457 KRW, a gap of about −63% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 038290?
No. The price is what the market pays today (12,090 KRW); the fair value is what the company's own numbers justify (4,457 KRW). For Macrogen Inc the two are 7,633 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Macrogen Inc worth?
The market values Macrogen Inc at about 131B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 12,090 KRW; our models calculate a fair value of 4,457 KRW per share.
What do the bullish and bearish scenarios say about 038290?
Our models span a range for Macrogen Inc: cautious scenario 3,342 KRW, base 4,457 KRW, optimistic 5,267 KRW per share (as of Sep 24, 2026, price 12,090 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Macrogen Inc (038290)?
Balance-sheet figures for Macrogen Inc (as of Sep 24, 2026): debt of 0.10 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is 038290 from its 52-week high?
Macrogen Inc trades at 12,090 KRW, about 38% below its 52-week high of 19,520 KRW and 13% above the low of 10,700 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 4,457 KRW is for.
Which stocks are comparable to Macrogen Inc?
From the same area (Healthcare) we also value MEDIPOST Co, Bioneer Corporation, Cell Biotech Co, Panagene Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Macrogen Inc stock attractive at the current price?
The data as of Sep 24, 2026: price 12,090 KRW, calculated fair value 4,457 KRW (−63%), Quality Score 48/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 038290 calculated?
We run Macrogen Inc through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 4,457 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Macrogen Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Macrogen Inc (038290)?
The closing price on Sep 23, 2026 was 12,090 KRW. Our model-based fair value is 4,457 KRW, about −63% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Macrogen Inc right now?
The price sits above even our optimistic bull case (5,267 KRW). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (48/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Macrogen Inc
How large is the market capitalisation of Macrogen Inc (038290)?
The market capitalisation of Macrogen Inc is 131B KRW (≈ $91.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Macrogen Inc (038290)?
The price-to-sales ratio of Macrogen Inc is 0.88 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Macrogen Inc (038290)?
The dividend yield of Macrogen Inc is 1.9%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Macrogen Inc (038290)?
The net margin of Macrogen Inc is 1.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Macrogen Inc (038290)?
The return on equity (ROE) of Macrogen Inc is −502% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Macrogen Inc (038290)?
On an EBIT basis the return on assets of Macrogen Inc is −1.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Macrogen Inc (038290)?
The operating margin of Macrogen Inc is 3.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Macrogen Inc (038290)?
Revenue at Macrogen Inc is growing +24.9% versus a year earlier (3y avg +12.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Macrogen Inc (038290)?
Earnings per share at Macrogen Inc are growing +621% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Macrogen Inc (038290) generate?
The free cash flow of Macrogen Inc is −13.7B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Macrogen Inc (038290) carry?
The net debt of Macrogen Inc is 42.4B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Macrogen Inc in the live analysis
One click puts Macrogen Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
